Qiagen (NYSE:QGEN - Get Free Report) updated its FY25 earnings guidance on Monday. The company provided earnings per share (EPS) guidance of ~$2.35 for the period, compared to the consensus estimate of $2.27. Qiagen also updated its FY 2025 guidance to 2.350- EPS.
Qiagen Price Performance
QGEN stock traded up $1.93 during mid-day trading on Friday, reaching $41.98. 1,723,550 shares of the company traded hands, compared to its average volume of 1,119,244. The company has a fifty day moving average price of $39.75 and a 200-day moving average price of $41.81. Qiagen has a 52-week low of $37.63 and a 52-week high of $49.30. The company has a market capitalization of $9.33 billion, a P/E ratio of 116.88, a P/E/G ratio of 2.39 and a beta of 0.62. The company has a debt-to-equity ratio of 0.38, a current ratio of 3.61 and a quick ratio of 3.09.
Qiagen (NYSE:QGEN - Get Free Report) last released its quarterly earnings results on Wednesday, February 5th. The company reported $0.61 EPS for the quarter, beating analysts' consensus estimates of $0.60 by $0.01. Qiagen had a net margin of 4.23% and a return on equity of 13.92%. As a group, analysts anticipate that Qiagen will post 2.26 earnings per share for the current year.
Analyst Upgrades and Downgrades
A number of equities analysts have recently commented on QGEN shares. Baird R W lowered shares of Qiagen from a "strong-buy" rating to a "hold" rating in a report on Wednesday, February 19th. Redburn Atlantic lowered shares of Qiagen from a "buy" rating to a "neutral" rating in a research report on Friday, April 4th. UBS Group cut their target price on shares of Qiagen from $50.00 to $48.00 and set a "neutral" rating on the stock in a report on Friday, February 7th. Robert W. Baird downgraded Qiagen from an "outperform" rating to a "neutral" rating and reduced their price target for the company from $52.00 to $42.00 in a report on Wednesday, February 19th. Finally, Morgan Stanley restated an "equal weight" rating and issued a $46.67 price objective (down from $48.61) on shares of Qiagen in a report on Monday, January 6th. Eight research analysts have rated the stock with a hold rating and three have issued a buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and an average target price of $47.71.
Check Out Our Latest Report on QGEN
About Qiagen
(
Get Free Report)
QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.
Read More
Before you consider Qiagen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Qiagen wasn't on the list.
While Qiagen currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
